OmanDocSign in

Curriculum · Cardiovascular and Hypertension

Cardiac biomarkers in acute coronary syndrome

What it is

Acute coronary syndrome is the clinical manifestation of myocardial infarct, and commonly the working diagnosis in a patient with new-onset chest pain suspected to be of cardiac ischemic origin. Clinical findings in combination with ECG and troponin are the mainstays of diagnosis, so the biomarker is one part of the answer and never the whole of it.

The four boxes are set by ST elevation together with the biomarkers:

How it is diagnosed

In myocardial infarction the laboratory finding is a rising troponin T/I, in contrast to angina pectoris. CK and CK-MB give the extent of cell damage, and BNP and myoglobin are also part of the panel. In stable angina, by contrast, cardiac enzymes (CK-MB/troponin) are normal.

When each one rises, peaks and returns is what makes the choice between them:

Myoglobin therefore rises first and returns to normal first, while troponin stays elevated for days, which is why troponin still finds an infarct in a patient who presents late.

What can go wrong

A raised troponin is not by itself an acute coronary syndrome. Takotsubo cardiomyopathy, also known as apical ballooning syndrome and stress-induced cardiomyopathy, generally occurs in postmenopausal women with a mean age of 62-76 years, and its clinical presentation is similar to that of acute coronary syndrome. It shows apical and midsegment left ventricular hypokinesis, or apical ballooning, with a new T-wave inversion and modest elevations in cardiac troponin, while a negative myocardial perfusion scan makes coronary artery disease or acute coronary syndrome unlikely. Evaluation with an EKG, cardiac biomarkers and imaging is needed to differentiate the two. Up to one-third of patients with Takotsubo cardiomyopathy have no identifiable stressor.